We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
From May 2021 to May 2024
By Cristina Roca
Sanofi SA and GlaxoSmithKline PLC said Wednesday that a single booster dose of their Covid-19 vaccine candidate delivered consistently strong immune responses.
Preliminary results from a clinical trial looking at the safety and immunogenicity of the booster shot showed that neutralizing antibodies increased regardless of whether participants had been initially vaccinated with the shot made by AstraZeneca PLC, by Pfizer Inc. and BioNTech SE or by Moderna Inc., the two pharmaceuticals companies said.
The Omicron variant of the coronavirus wasn't circulating during the trial, but the companies are now testing the ability of the shot to cross-neutralize against it, they said.
"This is the most comprehensive booster trial to date to explore boosting across different vaccine technologies used for primary vaccination," the companies said.
A Phase 3 trial for the vaccine is still under way, with results expected in the first quarter of 2022.
Write to Cristina Roca at cristina.roca@wsj.com
(END) Dow Jones Newswires
December 15, 2021 02:10 ET (07:10 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
